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Abstract
The synthesis and applications of the peptides are gaining increasing popularity 
as a result of the developments in biotechnology and bioengineering areas and for a 
number of research purposes including cancer diagnosis and treatment, antibiotic 
drug development, epitope mapping, production of antibodies, and vaccine design. 
The use of synthetic peptides approved by the health authorities for vaccine, for 
cancer, and in drug delivery systems is increasing with these developments. The aim 
of this book chapter is to review the recent developments in the use of peptides in 
the diagnosis of drug and vaccine systems and to present them to the reader with 
commercially available illustrations.
Keywords: synthetic peptide, solid-phase peptide synthesis (SSPS),  
peptide therapeutics, peptide vaccines, cell-penetrating peptides
1. Introduction
The aim of this chapter is to review some applications of synthetic peptides 
providing a brief knowledge about peptide synthesis. In the first part, information 
about the peptide synthesis was given in a very simple and readable format under 
the title of solid-phase peptide synthesis including a brief history, solid supports, 
linkers, protecting groups, and analysis method sections. Then the synthetic pep-
tide vaccine application of peptides was reviewed. After that, the topic of nuclear 
imaging-guided peptidic drug targets and labeling techniques and recent develop-
ments in therapy was discussed. In the last part, information about cell-penetrating 
peptides that can be used as molecular carries is mentioned with providing classifi-
cation and cellular uptake mechanism of them.
2. Solid-phase peptide synthesis (SSPS)
The specific characters of peptides (high bioactivity, high specificity, and 
low toxicity) have made them attractive therapeutic agents. The synthesis of the 
peptides may provide sufficient material to enable further studies and to determine 
the structure-activity relationships or may provide discovery of new analogues with 
improved properties [1–7]. The peptides are able to synthesize in three methods: in 
a solution medium, on a solid support, or as a combination of the solid and the solu-
tion synthesis. Although peptide synthesis is often carried out by the solid-phase 
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method, the solution method was preferred by the pharmaceutical companies in 
the 1970s and 1980s [8]. In the solution medium synthesis method, except for the 
reversible protection of the N-amino group of the first amino acid or fragment, the 
orthogonal protection of carboxyl groups of the second amino acid or the fragment 
is needed. On the solid-phase method, the synthesis is carried out on a solid sup-
port, also called a resin. The peptide is separated from the resin after each amino 
acid in the peptide sequence is sequentially bound. In the solid-phase technique, the 
peptide that bounded to the insoluble resin is separated without any significant loss 
during the washing or filtration of the resin. All reactions are carried out in a single 
reaction vessel, and possible losses are prevented during processes such as exchange 
and transfer of reaction vessels [9]. Another one is hybrid synthesis which is the 
composition of the solution and SPPS methods. Herein, the peptide to be synthe-
sized is obtained after the condensation from a solution of two or more suitable 
peptide sequences, which are obtained mainly by solid-phase synthesis [10].
The principle of peptide synthesis in the solid phase is quite simple. The peptide 
chain is attached to the stable solid phase. The peptide sequence remains bound 
on this resin for the duration of the synthesis. During the synthesis that includes 
deprotection, activation, and coupling steps, other soluble chemicals outside the 
resin beads are removed by filtration and washing. In the last stage, the desired 
product is separated from the solid phase by cleavage procedure. Purification 
and characterization procedures are carried out in the free solution of the desired 
product [11]. In SPPS, although there are two main strategies, the Boc approach 
requires the use of hard acids such as HF; thus the majority of synthetic peptides are 
nowadays synthesized by using Fmoc chemistry. The most important advantage of 
the Fmoc method compared to Boc strategy is that it does not require corrosive acids 
such as TFA during the synthesis cycle, and thus the synthesis can be automated. 
In this method, the N-terminal amine groups, the acid-labile side-chain protect-
ing groups, and the linkers forming the protecting group of the C-terminal amino 
acid are protected by the base-labile Fmoc group [12, 13]. Solid support materials 
(resins), linkers, protecting groups, and cleavage cocktail solutions are general 
components of the solid-phase peptide synthesis.
The resin is a spherical polymer ball bearing the active groups to which the first 
amino acid (indicates the first amino acid at the C-terminus of the sequence) of 
the sequence to be synthesized can be attached. The solid supports used in the 
solid-phase peptide synthesis must be stable against mechanical mixing, vari-
ous temperature conditions, and different types of solvents, must have a narrow 
range of resin bead sizes, and must have high swelling properties (should be able 
to swell up to 5–6 times in DCM, dimethylformamide (DMF), etc.); thus the 
reagents can reach the active regions of the resin. The solid support material is 
usually used in a size of about 100–200 mesh or 200–400 mesh, and the peptide 
chain is extended by the addition of amino acids on each other on the resin. The 
most common classes of resins are the classic polystyrene (PS) resins (cross-
linked with 1% of divinylbenzene (DVB)), the PS-functionalized polyethylene 
glycol (PEG) resins, pure cross-linked PEG resins, and polystyrene cross-linked 
with 1,6-hexanediol diacrylate resin (PS-HDODA) [14–20]. The solid support 
used in the synthesis can be of two kinds depending on whether or not the initial 
amino acid of the sequence to be synthesized is bound to the resin. Accordingly, 
there are two types of resin, either pre-loaded or unloaded, but pre-loaded resin is 
generally preferred. The pre-loaded resins differ depending on whether they are 
lowly loaded or highly loaded. When the highly loaded resin is used, aggregation 
of the peptide sequences growing on the resin increases, and this will lead to the 
deletion of an amino acid which is an undesirable situation; therefore, the use of 
lowly loaded resins is common [19].
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In order to bind the first amino acid to the resins, chemical structures containing 
functional group(s) called linker are attached. The number of these active groups on 
the resin (substitution) is important in calculating the theoretical yield of a peptide to 
be synthesized and in determining the amount of chemicals (deprotection, activation, 
coupling) required for the synthesis of a peptide. Depending on the functional group of 
the C-terminal end of the target peptide sequence, peptide acids or peptide amides can 
be synthesized by means of an ester or an amide bond, respectively. While the peptide 
acids are obtained using 4-benzyloxybenzyl alcohol (Wang), 2-(4-hydroxymethyl)
phenoxyacetic acid (HMPA), superacid-sensitive resin (SASRIN), and 2-chlorotrityl 
linkers, the peptide amides rink amide, 4-methyl benzhydryl amide (MBHA), and 
Sieber and primary amide (PAL) linkers are required (Figure 1) [13]. After the cleavage 
procedure, C-terminus of the peptide sequence remains ▬COOH or ▬NH2 depending 
on the type of the linker on the resin beads [13, 19, 21, 22].
The reaction between the activated carboxylic group of one amino acid and the 
amino group of another amino acid is needed for a peptide linkage. In order to pre-
vent side reactions from occurring, the remaining functional groups of each amino 
acid must be appropriately protected. For this purpose, many protecting groups are 
used to prevent the reaction of different types of functional groups. Because each 
amino acid contains different groups in its side chains, the protecting groups which 
prevent these groups from reacting vary according to the amino acid and used 
methodology (Fmoc or Boc chemistry). Some amino acids have not any functional 
groups to react in the side groups; only alpha-amino groups of these amino acids are 
protected by Fmoc or Boc [23–33].
Cleavage is one of the most important steps in solid-phase peptide synthesis. 
Exposing a resin to a cleavage cocktail is not an easy reaction; it brings a series of 
competitive reactions. Unless appropriate reagents and reaction conditions are 
selected in the cleavage process, the desired peptide can be irreversibly modified or 
damaged. Also, since the DMF used in the solid-phase peptide synthesis can inhibit 
TFA acidolysis, before starting the cleavage, the peptide-bound resin should be 
washed with DCM to remove all DMF. The goal of cleavage is to split the synthe-
sized peptide sequence from the resin while also removing amino acid side-chain 
protecting groups. For this process, strong acids such as anhydrous HF, TFMSA, or 
TMSOTf are used in Boc chemistry, while cocktails containing TFA are preferred 
in the Fmoc process  [12, 22, 34]. Additional substances such as EDT, phenol, 
and thioanisole called scavengers are put into the cleavage medium to prevent the 
cationic products occurring during the cleavage process to attack the amino acids 
that are having electron-rich side chains such as Trp, Tyr, and Met. Considering the 
amino acid types involved in the resin-linked peptide sequence synthesized by the 
solid-phase peptide synthesis method, it is decided to which type and how much 
scavenger add to the cleavage cocktail. For example, when there is one or more Trp 
in the peptide sequence, using EDT in the cleavage will substantially protect Trp 
against oxidation. Typically, the peptide-bound resin is treated using 95% TFA with 
gentle shaking for 1–3 h [12, 22, 34, 35].
The crude peptides synthesized by solid-phase peptide synthesis with the depro-
tection, activation, and coupling and cleavage steps are mostly analyzed on analyti-
cal HPLC using C18 columns at a concentration of 1 mg/mL with gradient elution 
method of water (0.1% TFA) and acetonitrile (0.1% TFA) as mobile phase. If purifi-
cation of the synthesized peptide is required according to the application to be used, 
preparative HPLC is used. For the analysis, the peptide should be dissolved in a 
minimum volume of 0.1% TFA in water, and the acetonitrile and water gradient elu-
tion is adjusted according to the polarity of the peptide [12, 22, 35–37]. The molecu-
lar weight of the synthesized peptide is confirmed by mass spectroscopy. The most 
commonly used methods are LC-MS, MALDI-TOF, and LC-QTOF-MS. Systems 
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with such a combination of chromatography and spectroscopy are useful for the 
complete characterization of synthetic peptides. While chromatographic analyses 
allow us to have knowledge about the peptides’ purity, the molecular weight of the 
peptides is determined by MS analyses. It is also found in some systems that deter-
mine the amino acid sequence of the peptide molecule like amino acid analyzer and 
LC-MS-MS. Information on structural properties of peptides can also be obtained 
by NMR and FTIR methods. With NMR and FTIR, the structures of the peptides 
are further elucidated via specific binding and functional groups [12, 35]. Moreover 
circular dichroism (CD) spectroscopy gives information about the conformation 
and secondary structures of polypeptides. This technique can be used to distinguish 
between random coil, alpha-helix, or beta-sheet structures [38, 39].
Figure 1. 
Some of the fundamental linkers used on the Fmoc-based SPSS [22].
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3. Peptide vaccines
The increase in studies on peptide vaccines in recent years shows that peptide 
vaccines will be an important part of new-generation vaccine systems. Vaccines 
are indispensable in protecting human and community health in terms of reducing 
infectious diseases, disability, and deaths and, most importantly, eliminating and 
eradicating the long-term disease. The development of the vaccine, which began 
with the observations of Edward Jenner at the end of the eighteenth century, has 
significantly reduced the number of infections and diseases until now [40–42]. 
Traditional vaccines (live-attenuated or inactivated vaccines) have been widely 
used over the last hundred years to develop effective vaccines against many diseases. 
However, the use of this technology is a source of concern because of the problems 
encountered in the preparation and use of such vaccines. The disadvantages of clas-
sical vaccines such as the increased need for safety, high cost in the production of 
large-scale vaccine preparations, high genetic variability of pathogens, side effects, 
and risk of leak of the disease agent have necessitated research to develop new tech-
nological vaccines [43, 44]. The basis for new vaccine technologies is the production 
of high-purity subunit vaccines that contain a small part of the pathogen necessary 
to generate an immune response. Subunit vaccines can be composed of polysac-
charides and proteins or their peptide fragments. Synthetic peptide vaccines consist 
of 20–30 amino acids containing the specific epitope of a corresponding antigen 
against various diseases. There is no limitation from cancer diseases to allergies 
in diseases targeted by peptide vaccines. The advantages of peptide vaccines have 
enabled peptides to be preferred in vaccine technology [45–48]. Although many 
peptide vaccine studies continue, there is no approved peptide vaccine for human 
use. According to the database of clinical studies maintained on ClinicalTrials.gov, 
in the search on the topic of peptide vaccine until mid-December 2018, 374 clinical 
trials in phase I, 272 clinical trials in phase II, 14 clinical trials in phase III, and 2 
clinical trials in phase IV have been found [47, 49]. Furthermore, it is reported in 
the literature that a veterinary peptide vaccine against canine parvovirus, which is 
targeted against animal diseases, is effective [50]. Advantages involved in the choice 
of peptide-based vaccine can be summarized as follows: Peptide-based vaccines 
are more reliable than classical vaccines because they are produced using chemical 
synthetic approaches almost exclusively. It does not produce any unwanted immune 
response as it does not contain biological material. Also, this situation eliminates 
the risk of biological contamination. The rapid, easy, inexpensive, and high-purity 
synthesis of peptides by microwave-assisted solid-phase peptide synthesis methods 
is an important advantage for the use of peptides in vaccine systems. These syn-
thesized peptide antigens can be fully characterized by analytical methods. “Cold 
chain” is not required generally during transport and storage of peptide vaccines. 
Peptide vaccines have high stability and are typically water-soluble. Allergic and/
or reactogenic effects are avoided by the usage of peptide vaccines. Peptide vaccines 
can be customized using the peptide epitope of one or more antigens [46, 51, 52].
Despite all its advantages, there are some limitations of peptide-based vaccines. 
The peptides alone are generally weakly immunogenic, have poor release properties 
and are easily undergo enzymatic degradation. These disadvantages can be over-
come using adjuvants and delivery systems. Adjuvants, derived from the Latin word 
“adjuvare,” which means “to help,” play a crucial role to the elicitation of a strong 
immune response to an antigen [49, 53–56]. The first step in the development of 
peptide vaccines is the identification of the structure of peptide epitopes which will 
provide effective and long-term immunity. After the synthesis and characterization 
of specific antigens to be determined, the appropriate adjuvant and delivery system 
selection is carried out [43, 46]. Currently, instead of classical adjuvants, the use of 
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new generation of more effective adjuvants is being studied. It is aimed to overcome 
the disadvantages of the traditional adjuvants with the development of modern 
adjuvants and delivery systems. Alum (insoluble salts of aluminum), which is a 
classical adjuvant, is a weak immune stimulant; its mechanisms of action are not 
fully elucidated and have a possibility of side effects. Emulsion adjuvants such as 
incomplete Freund’s adjuvant (IFA), complete Freund’s adjuvant (CFA), and lipid 
A are used; however, it is important to develop safer adjuvants due to their toxicity 
[46, 49, 57, 58]. Protein and synthetic polymer carriers play an important role in 
new-generation vaccine systems. The immunogenicity of peptide vaccines based on 
conjugation to protein and polymeric carriers is enhanced. Bovine serum albumin 
(BSA), keyhole limpet hemocyanin (KLH), human serum albumin (HSA), and 
ovalbumin (OVA) are the most preferred proteins in peptide-protein conjugates [51, 
59, 60]. In recent years, peptide-polymer conjugations using synthetic polymeric 
carriers have gained importance. Polymers to be selected in peptide-polymer con-
jugates, should be biocompatible, be relatively easy to synthesize and be modifiable 
according to the recommended use. This situation is pointed out that such polymers 
are important carrier candidates for peptide vaccines [61–63].
Nanoparticles are investigated for their potential use as vaccine delivery systems. 
The use of nanoparticles in peptide-based vaccines may be useful in elimination 
of limitations with small peptide antigens. It can play a critical role in increas-
ing the size of the antigen molecule, protecting the peptides from enzymatic 
degradation, and the delivery of the peptides to the targeted cells. Inorganic 
NPs, lipid-based NPs, polymeric NPs, and carbohydrates are common classes of 
nanoparticles. Especially polymeric NPs are of great interest for vaccination due to 
their biocompatibility and predictable degradation. In addition to natural polymers 
such as chitosan, dextran, and albumin, synthetic polymers such as polyesters, 
polyanhydrides, and polyamides can be mentioned. Mostly studied poly(lactic-co-
glycolic acid) (PLGA) is a synthetic copolymer composed of lactide and glycolide 
and approved by the European Medicine Agency (EMA) and US Food and Drug 
Administration (FDA) [64]. This polymer, which is biodegradable and biocom-
patible, is suitable for vaccine and drug delivery systems in humans. In the usage 
of polymeric nanoparticles as delivery systems for peptide vaccines, the peptide 
may be covalently/non-covalently attached to the surface of the particles through 
functional groups, or the peptide may be loaded into the nanoparticles [65–69].
Peptide vaccines are considered to be critical in the production of effective, safe, 
inexpensive, and easy to produce vaccines by the abovementioned advantages and 
the development of new adjuvants.
4. Utilizing of peptides as radio-theranostic agents
This part of the chapter will introduce the chemistry behind the radiolabel-
ing of peptide-based diagnostic and/or therapeutic pharmaceutical systems used 
for nuclear oncological imaging and present research related to drug discovery in 
various areas such as chemistry, bioengineering, nanoscience, and nuclear oncology 
[70]. Synthetic peptide-based drugs labeled by radiochemically different techniques 
are used in routine clinical applications for diagnosis and therapy of diseases. 
Peptides targeting the somatostatin receptor subtypes have been routinely applied 
for peptide receptor radionuclide therapy (PRRT) of neuroendocrine and prostate 
cancers. Tumor regression, lengthening survival, and increased quality of life were 
observed in the patients treated with 177Lu-/90Y-labeled peptide conjugates [71]. 
This section provides an overview of various targeting and labeling techniques for 
receptor-targeted imaging.
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4.1 Radiolabeled peptide analogues
PRRT with radiolabeled peptide pharmaceuticals is a suitable and promising 
next-generation therapy method for inoperable  patients with metastatic tumor. 
Radiolabeled peptide ligands are effective vectors for both detection and treatment 
of tumor cells overexpressing receptors specifically binding these ligands. Such 
radiopharmaceuticals, called as “theranostics,” can be administered for diagnosis 
besides treatment, depending on the type of radionuclide being bound to the 
peptide sequence. Especially somatostatin and prostate-specific membrane antigen 
(PSMA)-based peptide analogues have significantly influenced the staging and 
therapy of patients. Mentioned analogues are used in clinical routine as an integral 
part of the treatment [72].
4.1.1 Radionuclide therapy using somatostatin analogues
PRRT and radiolabeled somatostatin (SST) peptide analogues are highly effec-
tive treatment agents. Somatostatin is in the form of dominant but functionally 
less active 14 amino acids called SST-14 and SST-28 in the form of a larger and 
stronger 28 amino acids [73]. According to the structure-activity researches of 
SST-14, although the amino acid residues of Phe, Trp, Lys, and Thr which contain 
a β-turn are important for bioactivity, different amino acids may be replaced by 
the Phe and Thr amino acids for this bioactivity, whereas Trp and Lys residues are 
definitely required. Octreotide, lanreotide, vapreotide, and pasireotide, which are 
the 4SS analogue synthetic peptides, are currently used actively in routine clinical 
applications. The octreotide compound, which is the synthetic peptide compared 
to the natural SST, was found to be 19 times more effective in inhibition of growth 
hormone secretion [74]. The presence of the D-Phe at the N-terminal end and the 
L-Thr at the C-terminal end and the replacement of the L-Trp at position 8 with 
D-Trp ensure that the peptide is resistant to degradation [75]. The somatostatin 
receptor family contains five receptor subtypes, sst1–sst5. Most of the neuroen-
docrine tumors, especially subtype 2 (sst2), have a strong overexpression of sst. 
The clinical use of radiolabeled sst-targeting analogue [111In-DTPA0]octreotide 
initiated the development of numerous somatostatin analogues. This analogue is 
used as a theranostic agent in positive metastatic tumors. Tumor regression and 
survival improvement can be provided with [90Y-DOTA0,Tyr3]octreotide and 
[177Lu-DOTA0,Tyr3]octreotate. Several phase-1 and phase-2 PRRT trials were 
carried out using [90Y-DOTA0-Tyr3]octreotide. Tumor regression responses in the 
clinical studies with these agents in patients who suffered from GEP-NETs ranged 
from 9 to 33% [70]. As a result of the administration of the radiolabeled antagonist 
125I-JR11 and agonist 125I-Tyr3-octreotide in different tumors, it was found that the 
antagonist binds to the SSTR2 region at a rate of 3.8–21.8-fold higher [76]. This sig-
nificantly increased binding not only provides a more accurate localization in tumor 
and metastasis but also enables therapeutic interventions with radiolabeled SSTR 
antagonists to be more effective. Despite the low SSTR2 concentrations, tumors 
other than GEP-NETs and lung NETs have been targeted with SSTR2 antagonists; 
tumors of these types are breast cancer, medullary thyroid cancer, non-Hodgkin 
lymphomas, renal cell cancer, and small-cell lung cancer [76, 77].
4.1.2 Radionuclide therapy using PSMA analogues
PSMA has become an interesting target for the diagnosis and therapy of 
peptide receptors for small molecule ligands [78]. Since PSMA is often overex-
pressed in prostate cancer (PCa) cases, many different PSMA ligands are aimed 
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to be targeted by the same biological mechanism to diagnose and treat meta-
static castration-resistant prostate cancer (mCRPC). Many studies proved the 
superiority of 68Ga-PSMA PET/CT (positron emission tomography/computed 
tomography) as compared to CT, MRI, or bone scan for determination of metas-
tases for first staging at initial diagnosis [79, 80]. Imaging with PSMA in nuclear 
medicine substantially affected the detection and treatment of patients with 
prostate cancer. PSMA has been known to be promising and frequently preferred 
in advanced clinical studies because of providing preliminary information for 
different types of clinical conditions and detecting lesions with low PSA levels 
[81]. PET/CT data obtained using PSMA provides a noninvasive evaluation of 
PSMA expression and is used for restaging prostate cancer after radical prosta-
tectomy when PSA level is low [82]. Also, it can be applied in endoradiotherapy 
because of the intracellular internalization feature of PSMA. A small molecule 
inhibitor of PSMA ((S)-2-(3-((S)-1-carboxy-5-(3-(4-[124I]iodophenyl) ureido)
pentyl)ureido)pentanedioicacid; MIP-1095) has been administrated to evaluate 
potential therapeutic use of 131I-MIP-1095 in men with mCRPC [83]. Due to 
their molecular and specificity similarity, 68Ga-PSMA-11, 68Ga-PSMA-617, and 
68Ga-PSMA-I&T are abbreviated as 68Ga-PSMA. 68Ga-PSMA-11 biodistribu-
tion was known to correspond well to cellular detection of PSMA expression. 
68Ga-PSMA-617 and 68Ga-PSMA-I&T peptidic ligands demonstrated similar 
distribution and imaging properties [79].
4.1.3 Radionuclide therapy using other peptide analogues
For clinical applications, it is preferred that the peptide analogues are metaboli-
cally stable. The natural structure of the peptides makes them sensitive to peptidase 
and rapidly breaks down in blood and other tissues, so their potential uses as radio-
pharmaceuticals are restricted. Strategies for stabilizing peptides include incorpo-
rating biologically insoluble peptide bonds, stabilized amino acid derivatives, and 
cyclization [70]. Although the stability is advantageous, it is necessary to keep the 
nuclide in the tumor area for a long period of time for a good target-to-nontarget 
ratios and to rapidly clear the nuclide from nontarget tissues and blood. Researches 
on the topic of peptide-based radiopharmaceuticals have mostly been focused on 
receptor agonists. However, in recent years, somatostatin and bombesin antagonist 
peptide analogues have also been best shown for receptor targeting [72].
4.1.3.1 GRP receptor-targeting peptides
Overexpression of gastrin-releasing peptide receptors (GRPR) is seen in many 
human tumors, including prostate and breast tumors. Bombesin (BN), a 14-amino 
acid peptide with high affinity to the GRP receptor, is used for GRP receptor-
targeted tumor imaging and treatment. 111In- and 99Tcm-labeled BN analogues 
have been improved for SPECT imaging of GRP receptors. After a while, a novel 
DTPA-bound BN analogue, [111In-DTPA-ACMpip5, Tha6, βAla11, Tha13, Nle14]
BN (5–14) (Cmp 3), was synthesized. Replacement of the DTPA chelator in the 
111In-Cmp3 analogue with a DOTA makes the compound suitable for therapeutic 
use and diagnostic PET imaging. Another promising peptide-conjugated DOTA is 
177Lu-AMBA (DOTA-BN (7–14)), which exhibits good tumor-background ratios. 
The 177Lu-AMBA is excreted through the kidneys, but kidney excretion cannot 
be reduced by co-lysine injection because there is not any lysine in the peptide 
structure. Nowadays, it is the first choice in the targeting of 68Ga GRP receptors as a 
positron emitter radionuclide which provides shorter half-life and in-house radio-
labeling procedures as well as more accurate high-resolution PET images. Recently, 
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imaging studies have been studied to detect a GRPR and integrin αvβ3 dual target-
ing tracer 68Ga-BBN-RGD for PET/CT imaging of metastatic breast cancer [84]. 
Recent researches on BN analogues have focused on the DOTA chelating systems for 
multi-use options such as SPECT, PET, and PRRT [72].
4.1.3.2 NT receptor-targeting peptides
Neurotensin (NT) with 13 amino acids in its structure is expressed in the central 
nervous system, peripheral tissues, and gastrointestinal system [72]. Despite overex-
pression of neurotensin receptors in 75% of ductal pancreatic carcinomas, NT recep-
tor expression of endocrine pancreatic tumors, pancreatitis, and normal pancreatic 
tissue is negative (somatostatin positive) [85]. In a clinical study using 111In-labeled 
DTPA and DOTA-conjugated NT analogues, a number of specific changes were 
made to unnatural amino acids, indicating that the C-terminus plays a key role in the 
binding and biological properties of the peptide, and there is not a critical change in 
receptor binding activity of the peptide [72]. Because of high renal involvement of 
111In-NT analogues, PRRT is not considered appropriate with these analogues. With 
the discovery of three times more stable 99Tcm-labeled NT (NT-XIX) analogue, a bet-
ter tumor-to-kidney ratio, higher tumor involvement, and higher kidney excretion 
were achieved. 99Tcm-Demotensin, which was a high-stability NT analogue, has a 
higher tumor-to-intestinal and tumor-to-liver ratios, but the most appropriate ratios 
for imaging pancreatic tumors were obtained with the 111In-labeled analogues [86].
4.1.3.3 CCK2 receptor-targeting peptides
It has been determined that in the majority of medullary thyroid carcinomas 
(MTCs), in a high rate of small-cell lung cancer patients, stromal ovarian cancers, 
astrocytomas, and some other tumor types have cholecystokinin-2 (CCK2) recep-
tors. The CCK2 receptor-specific CCK peptide analogue was conjugated with 
DTPA for targeting this receptor [85]. The highest tumor uptake and too high renal 
involvement have been demonstrated at minigastrin analogues containing the 
CCK8 sequence. The addition of the histidine residues to the array almost reduces 
the kidney uptake by twofold. According to a study carried out in mice bearing the 
AR42J tumor, it was reported that the DOTA-conjugated HHEAYGWMDF peptide 
sequence exhibited the highest tumor-to-kidney ratio compared to all peptides 
studied [86]. Additionally, 99Tc-labeled N4-derived analogues of minigastrin have 
been synthesized [72]. Although studies with these radioligands are still in the 
initial stage for PRRT, they have significance features for the future.
4.1.3.4 GLP-1 receptor-targeting peptides
The glucagon-like peptide 1 (GLP-1) receptor which is overexpressed in human 
endocrine tumors, insulinomas, gastrinomas, and pheochromocytomas is a subtype 
of glucagon receptors used as a vehicle for in vivo tumor targeting. Because natural 
GLP-1 receptor agonists are metabolized quickly in the blood, a more stable and 
specific exendin peptide has been developed for use in the scintigraphic imaging of 
GLP-1 receptor-expressing tumors [72]. In the following years, 111In-DTPALys40-
exendin-4 [72] and [Lys40 (Ahx-DTPA-111In) NH2] exendin-4 conjugates with 
high tumor-background ratios have been optimized with using animal models [87]. 
In a clinical study based on the development of GLP-1 receptor-targeting analogues, 
PET/CT imaging with the 68Ga-NOTA-exendin-4 peptide analogue has been 




4.1.3.5 αvβ3 integrin-targeting peptides
αvβ3 integrins are a transmembrane protein that can be expressed in prolif-
erative endothelial cells and overexpressed in newly formed blood vessels where 
tumors are fed. The arginine-glycine-aspartic acid (RGD) tripeptide is essential 
for the interaction of extracellular matrix proteins to αvβ3 receptors. The cyclic 
RGD analogue containing these amino acids has the highest binding affinity. 
Many radiolabeled DTPA and DOTA-RGD conjugates with 111In, 90Y, 177Lu, 
68Ga, and 64Cu which provide SPECT and PET imaging and PRRT have been 
discovered in recent years. Monomeric, dimeric, and tetrameric RGD peptides 
are bound to DOTA for developing receptor binding affinity and then radiola-
beled with 111In. Although the monomeric and dimeric analogues have higher 
in vitro receptor affinity, the in vivo tumor uptake of the tetrameric analogue 
is higher. Also, it has been shown that multimeric RGD peptides are effective 
clinical molecules for in vivo determination of tumor angiogenesis in cancer 
patients [72].
4.2 Radiopeptides
In clinical practice, radiolabeled receptor ligands are used routinely for diag-
nostic imaging of overexpressed receptors and PRRT. Causes of clinical success of 
radiopeptidic receptor ligands are the following:
1. First, the presence of different radionuclides, having similar chemical proper-
ties, enables to label the same peptide with different radionuclides for different 
clinical purposes (SPECT, PET, PRRT).
2. Second, the influence of the high hydrophilic radiometal complex on peptide 
pharmacokinetics leads to rapid renal excretion and good target/background 
ratios.
3. Third, one-step in-house labeling methodology that facilitates the preparation 
of peptide radiopharmaceuticals in clinical routine [89].
The radioiodine which is used for radiolabeling of biologically active molecules 
is frequently preferred in PET imaging (124I), SPECT imaging (123/125I), treat-
ment of different cancer types (131I), and biodistribution and kinetic investigation 
of novel peptide radiopharmaceuticals (125I). Direct radioiodination is based on 
the substitution of an aromatic proton with *I+ (electrophilic radioiodide) and is 
successful only in electron-rich aromatic systems including activating substituents 
such as ▬OH, ▬NH2, ▬OR, ▬NHCOR, or ▬SR. For in situ production of *I+, 
chloramine-T (sodium tosylchloroamide) and iodogen (1, 3, 4, 6-tetrachloro-3a, 
6a-diphenylglycoluril) are utilized. Chloramine-T is added to the reaction medium 
with sodium metabisulfite to terminate the labeling reaction and prevent oxidative 
damage. Oxidative enzymes (lactoperoxidase) are used for substitution of peptide 
sequences that have high sensitivity to oxidation. Tyr- and also His-containing pep-
tides are readily radioiodinated in buffers such as phosphate buffered saline (PBS) 
or Tris (hydroxymethyl)-aminomethane (TRIS) at pH 7–8. Pre-radioiodination 
should be carried out by prosthetic groups. Selective prosthetic group conjugation is 
provided to the thiols with the help of pre-radioiodinated maleimides, and pre-
labeling of the corresponding peptide is carried out by the use of stannylated vinyl 
alkylating agents. In this way, tissue deiodinase and unfavorable structural condi-
tions for radioiodination can be overcome [90].
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Complex biomolecules such as peptides or proteins cannot be directly labeled 
with a highly basic [18F] fluoride by nucleophilic substitution and cannot tolerate 
labeling conditions. Activated aromatic precursors (NO2, CN, CI, etc.) are sub-
stituents bound to the leaving group in the ortho- or para-position. Many receptor 
binding peptides such as octreotide, bombesin, neurotensin, and RGD analogues 
have been labeled using [18F]FP-NP(4-nitrophenyl-2-[18F]fluoropropionate) or 
[18F]SFB(N-succinimidyl-4-[18F]fluorobenzoate) [91]. Chemoselective strategies 
provide a one-step prosthetic group labeling reaction by unprotected precursors. 
Reaction of a 18F-labeled aldehyde with aminooxy- or hydrazino-functionalized 
peptides so-called click chemistry has recently found most popular application [89]. 
A suitable chelating agent is required for the radio metallization of the peptides. 
When a chelating agent is conjugated with a receptor binding peptide, it can affect 
both the binding affinity of the peptidic ligand and peptide pharmacokinetics [89]. 
Radiolabeling of peptides with the oxo-technetium ions (TcO2
+,TcO+) is carried 
out by using peptide-bound tetradentate 99Tcm chelators (N3S or N4 scaffold). The 
peptides are coordinated with donor groups such as amine, carboxylate, or hydroxyl 
of the HYNIC (hydrazinonicotinic acid) chelator. In order to initiate the labeling 
reaction, a generator eluate (99Tcm-saline) should be added into a vial containing 
all the mixtures. For the labeling with 99Tcm, the [99Tcm(CO)3(H2O)3]
+; disodium 
boronocarbonate, Na2[HBCO2] (which also serves as an in situ CO source); and 
stannous ion, SnCI2 (reducing agent) are used [89]. 68Gallium labeling reaction 
is initiated by eluting the 68Ge/68Ga generator using hydrochloric acid (HCl) 
(0.05–0.60 M). Approximately 2 mL of the eluent is transferred to the reaction vial. 
Reaction vial containing a mixture of the lyophilized DOTA-peptide conjugate and 
sodium acetate buffer with the eluent is heated for 15 minutes at 100°C (25 min at 
90–95°C). The intermediate product is pushed through an extraction cartridge. The 
final product is analyzed to determine the labeling efficacy and purity [92].
5. Cell-penetrating peptides as molecular carries
The selective permeability and hydrophobic profile of the cellular membranes 
provide strict control of the molecular changes between the cytosol and the extracel-
lular environment [93–95]. Generally, peptides are selective and effective signaling 
molecules which bind to specific cell surface receptors that are involved in physi-
ological mechanisms such as peptides, hormones, neurotransmitters, growth factors, 
G-cell receptors (GPCRs), and ion channel ligands [96]. This characteristic of the 
peptides mentioned above and their attractive pharmacological profile represent a 
new starting point in the redesign and in-cell recruitment of molecules for therapeutic 
purposes [93–97]. Prior to the discovery of cell-penetrating peptides (CPPs), various 
methods have been used for cellular uptake of therapeutic agents and drugs, such as 
microinjection, electroporation, and liposome- and viral-based vectors, but these have 
disadvantages such as restricted bioavailability, low productivity, high toxicity, and 
low specificity [95]. After all these developments, in the late 1980s, a group of short 
peptides, such as the protein translocation site, membrane translocation sequence, 
Trojan peptide, or most commonly CPP, which serve as cellular uptake and delivery 
vectors of large molecules for therapeutic purposes, were identified [94, 96].
5.1 Definition and classification of CPP
CPPs are mostly defined as the short (containing less than 40 amino acid residues) 
partially hydrophobic and/or polybasic natural and synthetic peptides [94, 97]. 
With the discovery of CPPs, it has emerged as a new tool that allows cell membrane 
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translocation without significant membrane damage and at low concentrations with-
out using any chiral receptors. Due to the penetrating properties of these effective cell-
penetrating peptides, it opened new opportunities for medical treatment and delivery 
of therapeutic agents across cells in vivo. Furthermore, and even more importantly, 
interdisciplinary studies show that CPPs are able to assist in internalizing covalently 
or electrostatically conjugated bioactive cargos such as nucleic acids, polymers, 
liposomes, nanoparticles, and low-molecular-weight drugs, with dose-dependent 
efficiency, cheapness, degradability inside cells, and low toxicity [94, 95, 97].  
There are various classifications that rely on CPPs’ qualities. A categorization based on 
the origin of the peptide is one of the classifications. The first subgroup is also called 
protein transduction domains (PTDs); they are including protein-derived peptides 
such as TAT and penetratin. The second subgroup peptides called chimeric peptides 
may occur two or more motifs from other peptides. And the last subgroup in this 
category is synthetic peptides such as the polyarginine family [94, 98]. In addition, 
CPPs are categorized according to peptide sequences and binding abilities to the lipids, 
including non-amphipathic (naCPPs), primary amphipathic (paCPPs), and second-
ary amphipathic (saCPPs) CPPs. R9 and TAT (48–60) are examples of naCPPs that 
have a high cationic amino acid ingredient, and they are bound to the cell membrane 
with a high consideration of anionic lipids. The second subgroup of paCCPs such as 
transportan or TP10 have hydrophobic and hydrophilic residues straight from their 
primary structure. The third subgroup in this categorization is saCPPs such as penetra-
tin, pVEC, and M918. Their alpha-helix or beta-sheet patterns compose amphipathic 
properties [94].
In summary, in vitro cell and membrane modeling studies have shown that 
paCPPs are more toxic than naCPP and saCPPs.
5.2 Cellular uptake mechanism of CPP
5.2.1 Direct penetration
Direct penetration of CPPs eventuates along the membrane lipid bilayers 
without the contribution of receptors in low temperatures via energy-independent 
mechanism [93, 99]. There are three different types for the internalization pathway 
of CPPs by direct penetration [93].
5.2.1.1 Barrel-stave model
In the barrel-stave model, a different number of peptides are placed in the 
inside part of the membrane to give a hoop appearance. Each of these peptide 
molecules that provide the formation of membrane channels is likened to the 
boards that make up the barrel. Due to the appearance of the membrane, this 
model is called as the barrel-stave model. The barrel-stave model is carried out by 
an accumulation of peptides consisting of cationic peptides in the amphipathic 
helix structure. In this model, the hydrophilic sides of the peptides are contacted 
with the solvent, and the hydrophobic sides of the peptide come into contact with 
the lipid bilayer of the membrane, resulting in channels or pores in the membrane. 
The critical step in the barrel-stave model is that the peptides recognize each other 
while they are attached to the membrane. The peptide molecules then interact with 
the lipid molecules present in the membrane, and the peptides pass to the hydro-
phobic side of the membrane. By adding new monomers or small oligomers to the 
resulting structure, the width of the pores increases. The peptides act in this way 
even at very low concentrations once they penetrate the phospholipid membrane in 
the target cell [93].
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5.2.1.2 Carpet-like model
According to the carpet-like model, firstly an electrostatic interaction occurs 
between the phospholipid groups on the negatively charged cell membrane bilayer 
and the positively charged peptide monomers. The hydrophilic sides of the peptide 
monomers are bound to the surface of the target cell in such a way that they overlap 
the phospholipid groups in the membrane and cover the cell as a carpet. Once the pep-
tides in this state have reached a sufficient concentration, the peptide molecules rotate, 
reorganizing the hydrophobic portion of the membrane, causing a similar effect to the 
detergents and resulting in digestion of the membrane. On the contrary to the model 
of the barrel-stave model in the carpet model, the positively charged peptides cannot 
penetrate the hydrophobic parts of the membrane but instead are in a group with the 
hydrophilic parts facing one another. According to this mechanism, CPPs can be pres-
ent in various secondary structures, sizes, and linear or cyclic form [93].
5.2.1.3 Toroidal model
In toroidal model, after the halezonal peptides are parallel to the membrane, the 
polar groups of the membrane are replaced by the hydrophobic amino acid groups 
of the peptides. This leads to the formation of cleft that is vertical to the membrane 
in the hydrophobic part of the membrane, extending along the peptide and lipid 
groups. The difference of the toroidal model and the barrel-stave model is that the 
peptides are present vertically in the lipid membrane and always form the pores in 
combination with the lipid groups [93, 100].
Direct penetration pathway results in an irreversible membrane destabilization 
and can cause artifact distribution in cells [93, 99]. Therefore, it has been shown 
that CPP-cargo complexes can be taken into the cell by a mechanism known as 
endocytosis [93, 101].
5.2.2 Endocytosis
Endocytosis is a natural process that occurs in all cells via energy-dependent 
mechanism. Different types of pinocytic pathways have been identified, since 
they vary according to the access of different CPPs and conjugated cargo com-
plexes of CPPs [96].
5.2.2.1 Macropinocytosis
Macropinocytosis, which is related to the folding of the outer surface of the 
plasma membrane, is a nonspecific uptake of the extracellular compounds. It starts 
with an invasion of a membrane promoted by actinic cytoskeleton elements to cre-
ate a pocket and large endocytic vesicles containing different types of cargoes, and 
it finishes by the occurrence of vesicles called macropinosomes. Macropinocytosis 
has critical importance in the uptake of TAT and polyarginine [93, 102]. TAT uptake 
happens when using macropinocaytosis without the need for GATs or sialic acids, 
while plasma membrane-active proteins must be present [103]. Passive transport 
does not have actin remodeling, so passive transport is recommended for CPP 
penetration instead of macropinocytosis [104].
5.2.2.2 Clathrin-mediated endocytosis
Clathrin-mediated endocytosis is the specific uptake of CPPs that have been 
shown to have significance in the uptake of penetratine, TAT peptide, and other 
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CPPs after inhibition by hyperosmolar media [96]. The mechanism starts with 
the creation of a vesicle that is covered by a crystal on the interior surface of the 
cell membrane. After the coating of clathrin proteins by vesicles, it combines 
with an early endosome which moves via microtubules from the cell into the 
nucleus. Macromolecules carried on late endosome are fused with vesicles of the 
Golgi apparatus, which include pioneer of lysosomal hydrolase. After combining, 
lysosomal hydrolase enzymes are activated, and the late endosome turns into 
active lysosome. In the lysosome, the endocytosis substance is decomposed [105].
5.2.2.3 Caveolin-mediated endocytosis
Caveolin-mediated endocytosis which starts with a flask-shaped pit in a cave-
like membrane is a specific uptake of extracellular molecules. The CPP with its 
cargo is bound to the membrane, trapped in caveolae which are linked to actinic 
cytoskeletal elements, and then a protein tyrosine phosphorylation and actin depo-
lymerization are supported. Dynamin is the type of a GTPase liable for endocytosis 
in the eukaryotic cells that define other actin polymerization on the patch. Finally, 
cargo-loaded pouches are released inside the cytosol [106]. The various endocytic 
paths mentioned above have disadvantages such as low specificity, high dependence 
on the cell line used, and decreased cell viability [96, 107].
5.2.2.4 Escape from endosomes
Endocytosis of CPPs happens in two stages as endocytic entry and endosomal 
escape. Endosomal escape is a major step to prevent disruption of the cargo in the 
lysosomes and to allow the cargo to reach the extra-endosomal aim and to achieve 
its biological activity. Several models have been proposed to prevent endosomal 
escapes of CPPs. For instance, as a result of the electrical interaction between the 
negative charges of the endosomal membrane and the positively charged parts of 
the CPPs, the membrane that triggers the release of the vesicle content leads to 
stiffing and rupture. According to the other example, reduced pH develops the 
capability of CPPs to attach to the endosomal membrane and then raises intracellu-
lar circulation; as a result of which, the increment of endocytic vesicles may ensure 
better escape from the endosomal membrane [93, 95].
5.3 Factors affecting the mechanism of cellular uptake
5.3.1 Role of glycosaminoglycans
Initially the CPPs and the cell membrane interact via electrostatic linkage to 
proteoglycans called as glycosaminoglycans (GAGs) such as chondroitin sulfate 
B. Since these glycoproteins are present all over the cell membrane, they make the 
cell membrane negative charges, and they compose a platform that connects the 
CPPs or CPP/cargo binding to the cellular matrix. Recent studies have shown that 
GAGs are less critical for CPP uptake than the previous opinions [93, 103, 108].
5.3.2 Peptide secondary structure
The secondary structure of amphipathic and tachycardic peptides, the CPP con-
formation, and the length of the CPP sequence are very related to cellular uptake 
mechanisms.
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5.3.3 Role of arginine-rich residues
Structure-activity relationship studies show how important it is to identify the 
single residues in the CPP structure. When the CPPs are rich in arginine (especially 
for its guanidinium group), they can compose hydrogen bonds with polar lipid 
groups. The presence of arginines in the CPP has been related with a better uptake 
efficiency. In addition, replacement or wiping of arginines may reduce the cellular 
uptake [93, 104, 106].
5.3.4 Role of chirality
Although L amino acid and D amino acid peptides have similar effects against 
heparin, cell binding affinities of CPPs containing with amino acids in the L amino 
acid peptides are higher than D amino acid peptides. On the other hand, studies 
show that using of the D amino acid peptides in terms of increasing cell sensitivity 
and decreasing enzyme degradation gives better results [93, 101].
5.3.5 Role of concentration
It has been understood from the result of thermodynamic analyses that primary 
and secondary amphipathic CPPs can pass directly through the cell membrane at 
low micromolar concentrations, but non-amphipathic CPPs often use endocytosis 
even at low concentrations [109]. The concentration threshold of direct penetration 
depends on the type of CPPs, cargo, and cell lines [93].
5.3.6 Role of cargos
The existence of the cargo could affect the CPP uptake pathway. In addi-
tion, dimension and binding methodology are also shown by CPP translocation 
mechanism.
5.4 Molecular detection of CPPs’ cellular uptake
5.4.1 In cellular assay
The cellular researches largely propose to follow the CPP and/or the cargo uptake 
or to elicit the molecular mechanisms of the internalization. As a direct method, 
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF-MS) has been improved, and quantitatively determination of the 
amount of intact CPPs in the cells or in the cellular membranes can be provided 
[110]. Electron microscopy and Raman spectroscopy methods are also other 
biophysical methods used on cells [111].
5.4.2 Fluorescence-based assays
The covalent binding of a peptide to the fluorophore and the measurement of 
the fluorescence (fluorimetry) of the treated cells are the most common methods 
used to detect both CPP uptake and localization. In this approach, while confocal 
microscopy provides location information, the probes in the living cells allow indi-
rect quantification of the peptides. This method cannot show the molecular integ-
rity of internalized entities, so it cannot prove whether the peptide is still attached 
to the fluorescent probe in the cells. Furthermore, fluorescence quenching can cause 
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false-positive outcomes to detect the involvement in intracellular parts and transi-
tory binding areas [94, 96, 111]. Also, CPPs are known as cationic peptides, and 
they tend to link to the external of the cell membrane and may consequently lead 
to false-positive results [96]. Fluorescence-activated cell sorting (FACS) is another 
fluorescence approach used for quantitative measurement uptake of labeled CPPs. 
The cellular uptake of CPPs is measured by sorting cells which relied on fluores-
cence intensity by a cell sorter equipment [94]. The advantage of using the afore-
mentioned fluorescence-based protocols in the confocal microscopy process is that 
it allows distinguishing between internalized and extracellular peptides [94, 96].
5.4.3 Functional assays
These experiments, which are really suitable for biotechnological and thera-
peutic applications, can be carried out to determine the biological responses of 
linked molecules or cargos and to assess their mechanisms of uptake [1, 94]. These 
systems are based on internalizing antisense oligonucleotides (ONs) and upregula-
tion of luciferase gene expression [96, 112]. One of the functional assays is the 
splicing redirection assay. Due to elucidation of the mechanism of CPP-based cell 
internalization, cell lines are transfected by molecular methods with a plasmid 
carrying a luciferase gene and having their abnormal splice junction. Technically, 
the pre-mRNA of luciferase is correctly working, producing the expression of the 
protein whose activity can be utilized by luminescence when the abnormal joint 
site is blocked by antisense ONs [94, 96, 112]. Another system takes advantage of 
Cre-mediated recombination of an improved green fluorescent protein reporter 
gene causing EGFP expression [94, 96]. Since abnormal splicing of the luciferase 
pre-mRNA inhibits the translation of luciferase, if this junction is masked with 
antisense ON, translation of luciferase will result in the expression of activity of the 
protein, which can be assessed by luminescence. For the investigation of CPP-based 
transfer of different ONs, their internalization systems have been studied with 
transfected HeLa pLuc 705 cells [96, 112].
5.4.4 MALDI-TOF-MS assay
This approach is based on the quantification of internalization of peptides in 
living cells [111]. Furthermore, the quantity of both plasma membrane-bound and 
internalized peptides is accessible. In this method, an internal standard is needed 
for the ionization and the detection in MALDI which extremely depends on the 
structure of the molecule. Information about both the amount and molecular 
status (degraded or intact) of the internalized peptide can be obtained by using 
this method. The disadvantage of this method is that no data about the intracel-
lular localization of the peptide can be obtained. Nevertheless this method can 
get a knowledge about mechanisms of internalization (endocytosis versus direct 
translocation) and compare the relevant internalization affinities of CPP [96].
5.4.5 Membrane modeling assay
The assay often prefers to simulate the interaction, internalization, and direct 
translocation of CPPs through the inert plasma membrane [94, 96]. Membrane 
models are used in other techniques such as 31P-NMR, small-angle X-ray scattering, 
calcein or fluorescein-entrapped liposome leakage, and differential scanning calorim-
etry. These methods are not based on labeling of the CPP sequences with fluorescence 
agents [1]. Various researches have been performed by using giant or large unilamellar 
vesicles (GUV and LUV) to examine the translocation qualities of CPPs [96].
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Unfortunately, the precise mechanism of CPP internalization is still not 
fully elucidated. CPPs are internalized into the cells by direct or endosomal 
mechanisms, and these uptake mechanisms have been demonstrated by various 
molecular techniques. Though many recent studies have provided strong data for 
translocation of CPPs into cells, a better physical definition of these entry mecha-
nisms in cells by molecular techniques is still an open challenge for the future.
6. Conclusion
Consequently, this chapter provides a brief manual for anyone in the fields 
of solid-phase peptide synthesis, peptide vaccines, peptide theranostics, and 
cell-penetrating peptides. While the solid-phase peptide synthesis is the most 
convenient way to synthesize the peptides, the need for peptides with longer 
chain structure and peptides including unnatural amino acids has emerged with 
the identification of the pathological and physiological functions of the peptides 
through improvements in the molecular biology, bioengineering, and medical 
imaging areas. Synthetic chemistry will overcome these challenges, and peptides 
produced for different purposes, such as drugs, vaccines, and therapeutics, will be 
the solution for incurable diseases such as lots of epidemic disease and some cancer 
types with available materials and methods. It has been foreseen that the above-
mentioned researches can be investigated within the peptide science and technol-
ogy departments to be established academically in the next decade.
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